tirzepatide · Eli Lilly
What should I know about Zepbound?
Zepbound by Eli Lilly: Weight · sleep apnea. Cost, side effects, dosing as labeled, comparisons and the latest news, all sourced.
Start hereZepbound FAQ: Doses, Weight Loss, Side Effects, Storage and CostZepbound (tirzepatide) is approved for weight loss and for moderate to severe sleep apnea in adults with obesity. In trials, people lost up to 20.9% of body weight at 15 mg over 72 weeks; self-pay prices start at $299 per month.
Medications
Mounjaro vs Zepbound: Same Drug, Different Approved UsesMounjaro and Zepbound are both tirzepatide injections made by Eli Lilly, approved under separate FDA applications: Mounjaro for type 2 diabetes and cardiovascular risk, Zepbound for weight management and obstructive sleep apnea.Wegovy vs Zepbound: Weight Loss, Cost, Devices and Side EffectsWegovy (semaglutide) and Zepbound (tirzepatide) are both weekly injections for weight loss. In the one head-to-head trial, Zepbound produced 20.2% average weight loss versus 13.7% for Wegovy, though that study was open-label. Approved uses, devices and self-pay costs differ.Zepbound Doses List vs. Mounjaro: Every Pen and Vial StrengthZepbound and Mounjaro both come in six tirzepatide strengths: 2.5, 5, 7.5, 10, 12.5 and 15 mg. Each strength exists as a single-dose pen or vial (0.5 mL per dose) and as a multi-dose vial or KwikPen holding 2.4 mL, which is four weekly 0.6 mL doses.Zepbound for Sleep Apnea: Approval, Dose, Trial Results, and CostThe FDA approved Zepbound (tirzepatide) on December 20, 2024 for moderate-to-severe obstructive sleep apnea in adults with obesity. One-year trials showed 25 to 29 fewer breathing disruptions per hour and 18% to 20% weight loss; the trials tested it with and without PAP therapy, not stopping PAP.Zepbound Vials: What They Cost on LillyDirect and How to OrderA Zepbound single-dose vial holds one weekly dose of tirzepatide and costs $299 to $449 per month through LillyDirect self-pay, depending on dose. The $449 price for higher doses requires refilling within 45 days, and needles and syringes are sold separately.
Results
Best Foods to Eat on GLP-1 Medications (and the Ones That Cause Trouble)There is no official GLP-1 diet, but because these drugs cut food intake sharply (35% lower in one trial), dietitians point to protein at every meal, fiber, and fluids, while fried, sugary, and fatty foods can worsen side effects. Here is what the labels, trials, and dietitians actually say.Exercise on GLP-1 Drugs: What the Evidence Actually ShowsGLP-1 drugs produce major weight loss without supervised exercise, but roughly 25-39% of the weight lost is lean mass, versus 17.5% when lifestyle programs include resistance training. Exercise's clearest benefits show up in body composition and keeping weight off after the drug stops.GLP-1 Meal Plan Principles: What to Eat on Semaglutide or TirzepatideClinical reviews and dietitians give GLP-1 users the same core advice: smaller, more frequent meals with 20 to 30 grams of protein per meal, scheduled fluids, and gradual fiber, because 40% to 70% of patients get GI side effects. Here is what the guidance says, and what 'GLP-1 friendly' on a package means.GLP-1 Plateau: Why Weight Loss Stalls on Wegovy and ZepboundYes — a stall is a normal part of treatment. In tirzepatide trials, the median time to a weight plateau was 24.3 to 36.1 weeks depending on starting BMI, and about 90% of participants had plateaued by week 72.How Fast Does Zepbound Work? Timeline of Weight Loss ResultsZepbound's biggest share of loss came in the first 24 weeks — about 13.3% to 14.5% among adherent trial participants who lost at least 5% — with a plateau typically at 24 to 36 weeks and 72-week label averages of 15.0% to 20.9% depending on dose.How Much Protein on a GLP-1: What Published Targets SayPublished sources suggest roughly 1.0–1.5 g of protein per kg of body weight per day, or 80–120 g total, for adults losing weight on semaglutide or tirzepatide, with about 20–30 g per meal plus resistance training to help preserve muscle.Living on a GLP-1: Daily Life With Wegovy or ZepboundLiving on a GLP-1 is mostly a weekly rhythm: one shot, a fridge, and paperwork. The labels answer missed doses and travel storage (Wegovy single-dose pens last 28 days out of the fridge, Zepbound 21 days), while surveys show 32.4% work impairment at treatment start and stigma toward Ozempic users.
Drug pipeline
CagriSema: FDA Status, Weight Loss Results, and What Comes NextCagriSema is not FDA-approved yet. Novo Nordisk filed on December 18, 2025; the company expects FDA review in 2026, and trade press anticipates a decision by late 2026. In REDEFINE 1, weight loss was 22.7% if all stayed on treatment, 20.4% regardless of adherence.Eli Lilly vs Novo Nordisk: Who's Winning the Weight-Loss Drug Race?Eli Lilly leads the US GLP-1 market with about 57% of prescriptions to Novo Nordisk's 37%, but Novo's Wegovy pill leads the pill race with about 183K weekly prescriptions to Foundayo's 47.5K, per IQVIA estimates cited by analysts. Starting prices have fallen from about $1,000 to $149–$299 per month.Retatrutide: Trial Results, Side Effects, and When You Could Get ItRetatrutide is Eli Lilly's investigational once-weekly triple-agonist injection that produced up to 28.3% (70.3 lbs) average weight loss at 80 weeks in Phase 3. It is not FDA approved, cannot be prescribed, and Lilly plans to file for U.S. approval in Q1 2027.
GLP-1 culture
Celebrities on Mounjaro and Zepbound: Who Said WhatFour public figures have named Mounjaro or Zepbound themselves: Shaquille O'Neal with Zepbound, and Whoopi Goldberg, Sunny Hostin and Tori Spelling with Mounjaro. Serena Williams disclosed GLP-1 treatment without naming a brand, and several disclosures are paid corporate campaign partnerships.How Many Americans Take Zepbound? What the Published Numbers ShowNo official count of US Zepbound users has been published. What exists is Lilly's audited revenue: Zepbound made $13,542 million in 2025, up 175%, and Lilly says it was the most prescribed weight management medication that year.How Zepbound Overtook Wegovy in the US Weight-Loss MarketZepbound first beat Wegovy on new US prescriptions the week ending March 8, 2024, and by March 2026 Lilly held 60.1% of the US incretin market. Here is the timeline, the trial data, and the pricing moves behind the shift.
Cost
Cheapest Way to Get Tirzepatide Legally: 2026 PricesThe cheapest legal route depends on coverage: $25 for up to 3 months with a commercial plan that covers the drug, $50 per month through Medicare's GLP-1 Bridge starting July 1, 2026, near-zero on Medicaid in 13 states, or $299–$449 per month self-pay for the Zepbound KwikPen or vial.Does Insurance Cover Zepbound? How to Check and Appeal a DenialAs of July 2026, 60% of commercially insured people have no Zepbound coverage, leaving over 114 million uncovered, and 88% of those with coverage face prior authorization or step therapy. Here is how to check your own plan and what to do if it says no.Does Medicare Cover Zepbound? Routes, Costs, and the $50 BridgeMedicare won't pay for Zepbound or Mounjaro for weight loss alone. Two routes exist: the GLP-1 Bridge at $50 per month (July 1, 2026–December 31, 2027, Zepbound KwikPen only) and regular Part D coverage for diabetes, sleep apnea, or fatty liver disease. Without coverage, the manufacturer discount price is $299.00.Zepbound Cost Without Insurance in 2026: Cash Prices ExplainedWithout insurance, Zepbound costs $299 to $449 per month through Lilly's self-pay program, depending on dose. The $449 tier for higher doses requires refills within 45 days; Lilly's own pages give conflicting regular prices if you miss it, from $499 up to $1,049.Zepbound Savings Card: What You Pay and Who QualifiesThe Zepbound savings card can drop the cost to as little as $25 for a 1- to 3-month fill of the single-dose pen if your commercial insurance covers it, with savings capped at $1,300 per year. A separate KwikPen self-pay card offers cash prices from $299 a month.
Stopping and switching
Coming Off Compounded Semaglutide: What to Do When Your Program EndsThe FDA resolved the semaglutide shortage on February 21, 2025, and the shortage-based window that let pharmacies compound copies closed by May 22, 2025. Here is what that means for your program ending and how to move to an FDA-approved drug.Do You Have to Take Wegovy Forever? What the Evidence ShowsWegovy's label sets no stop date and obesity guidance strongly recommends continuing medication during weight maintenance. In withdrawal trials, people who stopped regained most of their lost weight within a year, while those who continued kept it off.GLP-1 Maintenance Dose: What the Research Says About Lowering ItYes, labels allow lower maintenance doses, and a 112-week trial found tirzepatide 5 mg kept weight loss at -16.6% versus -9.9% on placebo. Spacing doses out has weaker evidence: one 30-person case series and computer models.Switching From Wegovy to Zepbound: Doses, Timing, and What to ExpectThere is no official Wegovy-to-Zepbound conversion. The Zepbound label says every patient starts at 2.5 mg weekly for 4 weeks, with no exception for people coming from another GLP-1, and neither label specifies a washout — timing is your prescriber's call.What Happens When You Stop Taking a GLP-1?Stopping a GLP-1 usually leads to substantial weight regain within a year. In a pooled analysis of 8,993 adults across 6 studies, the difference in percent body-weight change between people who stopped and people who continued averaged 17.90%.
Compounded
Compounded Tirzepatide vs Zepbound: Cost and DifferencesCompounded tirzepatide was reported as low as $99 a month in 2025, but no audited current prices exist. Zepbound self-pay starts at $299–$449 a month, and compounded versions are not reviewed by FDA for safety, effectiveness, or quality.Compounded Tirzepatide: What It Is and Whether It's Legal in 2026Compounded tirzepatide is a copy of the active ingredient in Mounjaro and Zepbound made by a pharmacy, not a generic and not FDA-reviewed. Mass compounding became unlawful after the FDA declared the shortage resolved on December 19, 2024, with enforcement deadlines passing in February and March 2025.How to Spot Fake Mounjaro or Zepbound: Warning Signs to CheckThe safest test is where it came from: Lilly is the only lawful supplier of FDA-approved tirzepatide and never sells on social media. FDA has received more than 730 adverse event reports tied to compounded tirzepatide, and one Tennessee raid seized more than 300 counterfeit vials.Where to Get Zepbound Online: LillyDirect Costs and Telehealth FeesZepbound is prescription-only, so every online route runs through a prescriber. The channel documented on Lilly's own pages is LillyDirect, which charges $299 a month at 2.5 mg and $399 at 5 mg self-pay, with $449 at higher doses only if you refill within 45 days; Lilly-listed telehealth visits run from $25.
Getting started
Do I Qualify for Wegovy, Zepbound or Another GLP-1, and Who Decides?There is no application and no official qualification body. Three separate gates decide access: the FDA label, a prescriber's judgment, and your insurance plan. The weight-loss labels cover adults with obesity, or overweight plus at least one weight-related condition — and print no BMI number.How to Get a GLP-1 Prescription: Every Legitimate RouteWegovy, Zepbound and other GLP-1s require a prescription from a clinician who treats obesity — primary care doctor, NP, PA, specialist or telehealth prescriber. Here is what each route costs, from NovoCare self-pay at $149 to the Medicare GLP-1 Bridge at $50 per month.Questions to Ask Your Doctor About GLP-1 Medication Before StartingBring a written list to your GLP-1 appointment covering the approved use, eligibility, safety screening, drug interactions, pregnancy planning, dosing, follow-up, and cost. The questions come from FDA prescribing labels and ADA 2026 care standards, so every answer is checkable.What to Expect in Your First Month on a GLP-1 MedicationThe first month on Zepbound, Wegovy, Ozempic, or the new GLP-1 pills is a titration phase, not a results phase. Zepbound starts at 2.5 mg weekly and Wegovy at 0.25 mg weekly, each held for 4 weeks before any increase, per the FDA labels.Which GLP-1 Is Right for Me? How Doctors Actually DecideThere is no single best GLP-1. Doctors match the drug to the indication you meet, the format you can keep up with, dose ceilings, side effects, and your other medicines — the ADA says to individualize treatment, and even a 5–7% weight loss improves glycemia.
Side effects
Does Zepbound Cause Hair Loss? What the Label and Studies ShowHair loss is a listed adverse reaction on the Zepbound label, reported by 4–5% of patients in trials versus 1% on placebo, mostly women, and the label ties it to weight reduction. Causality has not been established.Mounjaro Lawsuits: What's Alleged and Where Cases Stand in 2026Mounjaro is named in MDL 3094, the federal GLP-1 gastrointestinal injury litigation, and Zepbound is among Lilly's medicines at issue per its May 2026 brief. Nearly 3,000 gastroparesis suits were pending as of December 2025; a Daubert hearing was set for September 14–18, 2026.Mounjaro Side Effects: What the Label Reports and How OftenThe most common Mounjaro side effects are nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia, and abdominal pain; nausea reached 18% at the 15 mg dose in placebo-controlled trials. The label also carries a boxed warning about thyroid C-cell tumors seen in rats.Tirzepatide vs Semaglutide Side Effects: What Direct Comparison ShowsSURMOUNT-5 (751 adults) found mostly mild-to-moderate GI side effects in both arms; a 46,620-pair real-world study found an HR of 1.07 for serious GI events with tirzepatide vs semaglutide. Label percentages cannot be compared across drugs.Zepbound and Alcohol: Label Warnings and Drinking EvidenceThe Zepbound and Mounjaro Drug Interactions sections cover insulin, sulfonylureas, and oral medications. A study of more than 120 million US health records linked tirzepatide to about half the rate of new alcohol use disorder diagnoses (HR 0.47), and a 42-person randomized trial is underway.Zepbound Side Effects: Complete List of What Trials ShowIn the label's main safety pool of 2,519 adults, digestive problems dominate: 56% had a GI reaction on each Zepbound dose versus 30% on placebo, and 4.8% to 6.7% stopped treatment over side effects. The boxed warning covers thyroid C-cell tumors seen in rats, not proven in humans.
News timeline
Eli Lilly GLP-1 News 2026: The Biggest Stories Through Mid-SeptemberEli Lilly's 2026 so far: FDA approval of the oral GLP-1 pill Foundayo on April 1, 2026, a cardiovascular approval for Mounjaro, record retatrutide weight loss of 70.3 lbs (28.3%), and a false-advertising lawsuit from Novo Nordisk filed July 21.Tirzepatide History: Mounjaro and Zepbound Year by YearTirzepatide reached the U.S. market as Mounjaro for type 2 diabetes on May 13, 2022, then as Zepbound for weight management on November 8, 2023. Trial weight loss ran from 15.7% in people with diabetes to 22.5% in SURMOUNT-1, and a 2024 head-to-head trial showed 20.2% for Zepbound vs. 13.7% for Wegovy.Zepbound News 2025: The Biggest Stories on Price, Coverage and CompetitionIn 2025, Zepbound and Mounjaro news shifted from shortages to money: Medicare opened limited coverage, CVS dropped Zepbound from its biggest formularies, and Lilly cut cash vial prices to $299–$449 per month by December.
The drugmakers
Eli Lilly Pipeline: What Comes After ZepboundLilly's next obesity drug, retatrutide, delivered 28.3% (70.3 lbs) average efficacy-estimand weight loss at 80 weeks in Phase 3, with a BLA planned for Q1 2027. Behind it sit eloralintide, bimagrumab and the already-launched pill Foundayo. Here is where each asset stands.Who Makes Mounjaro and Zepbound? Eli Lilly, ExplainedMounjaro and Zepbound are both made by Eli Lilly and Company, an American drugmaker headquartered in Indianapolis, Indiana. Both brands contain the same active ingredient, tirzepatide, but they are FDA-approved for different uses.
Foundayo
Foundayo vs Wegovy Pill: How the Two Oral GLP-1s CompareFoundayo (orforglipron) and the Wegovy pill (oral semaglutide 25 mg) are both once-daily weight-loss tablets, but no head-to-head weight trial exists. The key differences are dosing rules, approved uses, and cost.How Much Does Foundayo Cost? Prices With and Without InsuranceFoundayo (orforglipron) costs $149–$299 per month self-pay, as little as $25 per fill with commercial insurance that covers it, and $50 per month for eligible Medicare Part D patients through the GLP-1 Bridge. Lilly's list price is $649.00 per 30-day supply.
Who they're for
GLP-1 After Bariatric Surgery: Does It Work for Weight Regain?Yes — the evidence says it can work. In a 68-week randomized trial, semaglutide 2.4 mg once weekly produced −18.0% body weight versus +0.4% on placebo in people with poor results after gastric bypass or sleeve, with no new safety concerns. No GLP-1 is FDA-approved specifically for post-bariatric use.GLP-1 and Men's Health: Testosterone, Erections, Sperm and MusclePost hoc analyses reported in a conference abstract suggest women lose about 40% more weight than men on GLP-1 drugs. A review of five trials found no negative impact on hormones, sexual function or sperm quality, with possible testosterone gains for men whose low T is driven by obesity [1][10].Who Should Not Take GLP-1 Drugs: Contraindications and WarningsOnly two things rule out these drugs outright: a personal or family history of medullary thyroid carcinoma or MEN 2, and hypersensitivity to the drug or its ingredients (Wegovy's label says "known" hypersensitivity; the other three say "serious"). Everything else is a warning or "not recommended."
Insurance
GLP-1 Prior Authorization Requirements: What Insurers Ask ForInsurers approving Wegovy or Zepbound typically require a BMI of 30 or higher (27 with a comorbidity), documented participation in a weight management program, and proof of at least 5% weight loss at renewal. Exact rules vary by plan and change often.How to Appeal a Zepbound Denial: Steps, Deadlines, and Your OddsIf your insurer denied Zepbound or another GLP-1, appeal through the plan first, then external review — a written request within 4 months. Among Medicare Advantage denials appealed in 2024, 80.7% were overturned, though only 11.5% were appealed at all.How to Get Wegovy Covered by Insurance (and What to Do If It Says No)Coverage for Wegovy and Zepbound is decided by your plan's formulary and prior-authorization rules, not your prescriber. In 2026, 7% of commercially insured people — nearly 13 million — have no coverage for any weight-loss GLP-1, and 88% of those with coverage face added requirements.Is Wegovy HSA Eligible? Paying for GLP-1 Drugs With HSA or FSA FundsYes. Wegovy, Zepbound, Ozempic and other GLP-1s can be paid from an HSA or FSA when prescribed to treat a physician-diagnosed disease such as obesity or diabetes. The 2026 HSA limit is $4,400 self-only and $8,750 family; the FSA limit is $3,400.Medicaid GLP-1 Coverage by State in 2026Thirteen state Medicaid programs covered GLP-1s for obesity as of January 2026, down from 16 in October 2025. Every state still covers them for type 2 diabetes, and Massachusetts and Rhode Island are the latest states moving to drop weight-loss coverage.Medicare GLP-1 Bridge Program Eligibility and CostsThe Medicare GLP-1 Bridge runs July 1, 2026 through December 31, 2027 and gives eligible Part D beneficiaries certain GLP-1 weight-loss drugs for a $50 copay per monthly fill. Eligibility requires age 18 or older, an eligible Part D plan type, and BMI criteria met when GLP-1 therapy started.Novo Nordisk Patient Assistance Program: Wegovy and Lilly CaresFree GLP-1 medicine through a manufacturer program is real but narrow. Novo Nordisk's PAP gives free medicine only to Medicare or uninsured patients under income limits of 200%–400% of the federal poverty level, while Lilly Cares' current lists include Trulicity but not Zepbound or Mounjaro.
How it works
How Does Zepbound Work? GIP and GLP-1, Explained SimplyZepbound (tirzepatide) activates two gut-hormone receptors at once, GIP and GLP-1, which is why it is called a dual agonist. It starts at 2.5 mg once weekly for 4 weeks and can go up to a 15 mg weekly maintenance dose.How Long Does Tirzepatide Stay in Your System? (Mounjaro, Zepbound)Tirzepatide has a half-life of about 5 days, so after your last weekly shot the drug keeps working its way out of your blood for roughly 25 days — about five half-lives. Here's what the labels and FDA review actually say.Semaglutide vs Tirzepatide: Which Works Better for Weight Loss?Semaglutide (Ozempic, Wegovy) targets one receptor; tirzepatide (Mounjaro) targets two. In the only head-to-head trial, tirzepatide produced −20.2% body weight vs −13.7% for semaglutide at 72 weeks.Tirzepatide and Birth Control: Does It Affect the Pill?Yes — the Mounjaro and Zepbound labels say tirzepatide can affect absorption of oral contraceptives, and advise switching to a non-oral method or adding a barrier method for 4 weeks after starting and after each dose increase.
How to use
How Long Can Ozempic Be Out of the Fridge? GLP-1 Storage RulesAn Ozempic pen can stay out of the fridge for 56 days after first use at 59°F to 86°F. Zepbound and Mounjaro single-dose pens get 21 cumulative days, and their multi-dose vials and KwikPens get 30 days. All of them must be thrown away if frozen.How to Dispose of GLP-1 Needles and Pens (and What Your State Allows)FDA's rule is two steps. Your state's rule is the one that decides what happens to the full container, and four states do not let it go in household trash at all. Here is the whole process, plus the free container programs most people do not know exist.How to Inject Zepbound: Step-by-Step for Each DeviceZepbound comes in four devices, and each one is injected differently: the single-dose pen uses a lock ring and purple button, vials need a syringe, and the KwikPen label calls for priming before every weekly dose. Here is what Lilly's FDA-approved Instructions for Use say for each device.How to Use a Wegovy Savings Card at the Pharmacy: Codes and NDCsShow the Wegovy savings card to your pharmacist at pickup; it carries BIN, PCN, GRP and ID numbers that route the claim to SS&C Health with the right other coverage code (08, 03, or 00/01), and claims must be submitted within 180 days of the fill date.Missed Dose of Ozempic or Another GLP-1: What the Labels SayEach GLP-1 product has its own missed-dose rule. The Ozempic label allows the shot within 5 days of the missed dose; Wegovy injection depends on whether the next dose is more or less than 2 days (48 hours) away; Mounjaro and Zepbound allow 4 days (96 hours).Zepbound Vial: How to Draw Up Your Dose in mL or UnitsFor a single-dose Zepbound vial, draw the syringe to the 0.5 mL line. A multi-dose vial delivers four 0.6 mL doses. Doses are measured in mL, not units, and needles and syringes are sold separately.
The GLP-1 market
How Many People Take GLP-1 Drugs in the US? The Numbers by QuarterAbout 11 million unique US patients were on a GLP-1 as of Q2 2025, and the class passed 9 million prescriptions a month by end of 2024. Here is how Wegovy, Zepbound, the Wegovy pill and Foundayo split the market since.The Cheapest Place to Buy Wegovy or Zepbound Right NowAs of 2026 price snapshots, the lowest posted self-pay prices run from $149 a month for oral GLP-1s at Amazon Pharmacy to $299-$449 for Zepbound through LillyDirect, with CVS voucher pricing as low as $149. Verify every price before buying, since several are introductory or time-limited.Where Is Ozempic Made? What's Confirmed About US GLP-1 PlantsLilly is building a $9 billion site in Lebanon, Indiana, to make the active ingredient for Mounjaro and Zepbound, and it fills injectable products at a Wisconsin plant. The sources used here do not document where Ozempic, Wegovy, or Rybelsus semaglutide is made.
Trial evidence
How Much Weight Do You Lose on Zepbound? Trial Results by DoseIn the main 72-week trial, adults without diabetes lost an average of 15.0% on 5 mg, 19.5% on 10 mg, and 20.9% on 15 mg of Zepbound, versus 3.1% on placebo. Losses ran smaller with type 2 diabetes and in real-world data.Semaglutide vs Tirzepatide: Which Is Better for Weight Loss? SURMOUNT-5 ExplainedIn the first published head-to-head randomized trial in adults with obesity without diabetes, tirzepatide produced 20.2% weight loss versus 13.7% for semaglutide over 72 weeks. Here is what the study showed, plus side effects, heart evidence, and how clinicians say to choose.SURPASS-CVOT Results: What Tirzepatide Did for the Heart, ExplainedSURPASS-CVOT found tirzepatide (Mounjaro) noninferior to dulaglutide (Trulicity) for cardiovascular death, heart attack, or stroke: HR 0.92; 95.3% CI 0.83 to 1.01. Superiority was not met. A 16% lower all-cause death rate and kidney benefits were favorable but not statistically protected findings.Tirzepatide Clinical Trial Results: What the Studies ShowIn phase 3 trials, tirzepatide produced 15.0–20.9% mean weight loss over 72 weeks in adults with obesity (vs 3.1% on placebo) and cut HbA1c by 1.87–2.8 points across the diabetes trials, beating semaglutide 1 mg and two insulins head to head. Heart, kidney, and liver trial results were not verified for this page.What Happens If I Stop Taking Zepbound? What the Trials ShowIn the SURMOUNT-4 withdrawal trial, people who stopped tirzepatide regained an average of 14.0% of body weight in 52 weeks, while those who continued lost another 5.5%. Only 16.6% of stoppers kept most of their loss.When Will I See Results on Zepbound? Week-by-Week TimelineIn trials, 82% of adherent Zepbound users lost 5% or more of their body weight by week 12, and average loss at week 72 ranged from 15.0% on 5 mg to 20.9% on 15 mg. Here is how the timeline unfolds, and what a slow start really means.
FDA and regulation
Is Compounded Tirzepatide Legal in 2026? What FDA Rules SayNo. Mass compounding of tirzepatide became unlawful after FDA resolved the shortage in December 2024 and grace periods closed in 2025. Only narrow 503A exceptions remain, and FDA has received more than 730 adverse event reports for compounded tirzepatide.Is Tirzepatide Still in Shortage? FDA Status and TimelineNo. Tirzepatide injection (Mounjaro, Zepbound) came off the FDA drug shortage list on October 2, 2024, and FDA re-confirmed that decision on December 19, 2024. An appeals court upheld the removal on August 27, 2026.Tirzepatide Approvals by Country: Mounjaro and Zepbound WorldwideTirzepatide is approved for type 2 diabetes and weight management in the US, EU, UK, Canada, Australia, Japan, China and India. The US approved Mounjaro for diabetes on May 13, 2022 and sells the weight-loss version as Zepbound; the UK and Europe use the Mounjaro name for both uses.Tirzepatide FDA Approval History: Mounjaro and Zepbound, Year by YearThe FDA approved tirzepatide as Mounjaro (NDA 215866) on May 13, 2022 for type 2 diabetes and as Zepbound (NDA 217806) on November 8, 2023 for weight management. Later approvals added sleep apnea (December 20, 2024), pediatric diabetes (December 19, 2025), and cardiovascular risk reduction (August 27, 2026).
Emerging uses
Microdosing Zepbound: What the Evidence Actually ShowsMicrodosing Zepbound has no clinical definition, and clinicians say there is no robust evidence it works at very small doses. The label approves 5, 10, or 15 mg weekly for maintenance, and SURMOUNT-MAINTAIN found 5 mg held weight loss at −16.6% versus −9.9% for placebo.Tirzepatide and Heart Failure: What the SUMMIT Trial ShowedIn the SUMMIT trial, tirzepatide cut the combined risk of cardiovascular death or worsening heart failure by 38% (HR 0.62) in adults with HFpEF and obesity, but neither Zepbound nor Mounjaro is approved for heart failure in the US or EU.Tirzepatide for PCOS: Evidence, Approval, and Pregnancy RisksTirzepatide (Mounjaro/Zepbound) is not FDA-approved for PCOS. One small 16-week trial found 10.4 kg weight loss and 53.6% menstrual recovery when added to metformin, but a larger placebo-controlled trial is still recruiting.What Else Can Tirzepatide Treat? Approved and Studied UsesTirzepatide (Mounjaro, Zepbound) is FDA-approved for type 2 diabetes, weight loss, sleep apnea, and — since August 2026 — reducing heart attack and stroke risk in adults with diabetes at high risk. Heart failure, diabetes prevention, and fatty liver show positive trials but no approval.Zepbound for Sleep Apnea: What the Evidence Actually ShowsZepbound (tirzepatide) was FDA-approved in December 2024 for moderate-to-severe obstructive sleep apnea in adults with obesity. In 52-week trials it cut AHI by about 20-24 events per hour versus placebo, but sleep medicine groups say it is a tool alongside CPAP, not a replacement.
Common questions
Mounjaro questions people ask: uses, cost, doses, and moreMounjaro is Eli Lilly's brand of tirzepatide, a once-weekly injection FDA-approved for type 2 diabetes in adults and children 10+, and to cut heart attack and stroke risk in high-risk adults. Its list price is $1,112.16 per month's fill; self-pay starts at $499.Zepbound Questions Answered: Cost, Doses, Savings, Sleep ApneaZepbound is Eli Lilly's once-weekly tirzepatide injection, approved for weight loss and for moderate-to-severe obstructive sleep apnea in adults with obesity. Without insurance, self-pay prices run $299 to $449 per month, with the $449 price for 7.5 mg and above requiring refills within 45 days.
Alternatives
Liraglutide
Recent Zepbound news
Full timeline- Research and trials
CVS Caremark adds Zepbound back to commercial formularies starting October 1